Consequently, STING agonists hold significant promise as a therapy for reshaping the immunosuppressive TME (Wehbe et al., 2021), as they can reverse its immunosuppressive nature and sensitise breast cancer to immunotherapy (Chen et al., 2020; Zhang L. et al., 2022; Shen et al., 2022). This evidence concerns the gene STING1 and breast carcinoma.